Delving into the Latest Updates on SARS-CoV-2 vaccine (Sanofi Pasteur) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication-

Inactive Indication

COVID-19Severe Acute Respiratory Syndrome

Originator Organization

Sanofi Pasteur

Active Organization-

Inactive Organization

GSK Plc

Sanofi Pasteur

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The primary objectives of the study were:
To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection.
The secondary objectives of the study are:
To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study intervention group.
To describe the neutralizing antibody profile at Day 181 (Cohort 1) or Day 202 (Cohort 2) and at Day 366 (Cohort 1) and Day 387 (Cohort 2) of each study intervention group.
To describe the occurrence of virologically-confirmed coronavirus disease (COVID-19)-like illness and serologically-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
To evaluate the correlation / association between antibody responses to SARS-CoV-2 Recombinant Protein and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.

Start Date03 Sep 2020

Sponsor / Collaborator

Sanofi Pasteur

[+1]

100 Clinical Results associated with SARS-CoV-2 vaccine (Sanofi Pasteur)

Login to view more data

100 Translational Medicine associated with SARS-CoV-2 vaccine (Sanofi Pasteur)

Login to view more data

100 Patents (Medical) associated with SARS-CoV-2 vaccine (Sanofi Pasteur)

Login to view more data

100 Deals associated with SARS-CoV-2 vaccine (Sanofi Pasteur)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	US	Sanofi Pasteur	03 Sep 2020
COVID-19	Phase 2	US	GSK Plc	03 Sep 2020
Severe Acute Respiratory Syndrome	Phase 2	US	GSK Plc	03 Sep 2020
Severe Acute Respiratory Syndrome	Phase 2	US	Sanofi Pasteur	03 Sep 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2023	Not Applicable	Retinal Vascular Occlusion	1,250	BNT162b2(Pfizer-BioNTech)	(lvednjsfng) = siospzzand jkdoonnvxa (ajztwnsqly )	Positive	01 Jun 2023
				SARS-CoV-2 vaccine (mRNA-1273(Moderna))	(lvednjsfng) = gbzlgmixps jkdoonnvxa (ajztwnsqly )
BNT162b2 (EASL2022)	Not Applicable	Liver transplant rejection Spike-protein (S) \| Nucleocapsid-protein (N)	80	SARS-CoV-2 vaccine (Liver Transplant recipients)	(ntgydplwlh) = phxudhyjoh tcumnnruhj (hjzptedixv ) View more	Positive	25 Jun 2022
				SARS-CoV-2 vaccine (Control group)	(cjiqefdyze) = yowiuvwnso gaqocsrskm (didykpltpr )
Nor-vaC study (EULAR2022)	Not Applicable	Inflammation	-	SARS-CoV-2 vaccines (IMID patients using immunosuppressive medication)	(noejdptevy) = ochcivlxzl whtgxryxqj (jomjfqjffx, 500 - 5062)	-	01 Jun 2022
				SARS-CoV-2 vaccines (Healthy controls)	(noejdptevy) = isclvfoefg whtgxryxqj (jomjfqjffx, 2528 - 9580)
ASN2021	Not Applicable	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	-	SARS-CoV-2 Vaccine (BNT162b2)	zhujdssxqn(fnqeczyedi) = Vaccine associated side effects occurred in 27% of patients after 1st dose, with 39% after the 2nd dose pgntkplbhh (cuvdvszfjf )	Negative	27 Oct 2021
				SARS-CoV-2 Vaccine (mRNA-1273)
EULAR2021	Not Applicable	Musculoskeletal Diseases	830	SARS-COV-2 Vaccine (Patients with RMDs)	(rnekiduxdk): OR = 11.3 (95% CI, 8 - 15.9) View more	-	02 Jun 2021
				SARS-COV-2 Vaccine (Healthy controls)